Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience

2018; Elsevier BV; Volume: 131; Issue: 17 Linguagem: Inglês

10.1182/blood-2017-10-810044

ISSN

1528-0020

Autores

Susan O’Brien, Richard R. Furman, Steven Coutré, Ian W. Flinn, Jan A. Burger, Kristie A. Blum, Jeff P. Sharman, William G. Wierda, Jeffrey A. Jones, Weiqiang Zhao, Nyla A. Heerema, Amy J. Johnson, Ying Luan, Danelle F. James, Alvina D. Chu, John C. Byrd,

Tópico(s)

Immunodeficiency and Autoimmune Disorders

Resumo

Key Points Our 5-year experience shows sustained single-agent efficacy of ibrutinib in CLL patients, with complete response rates increasing over time. Long-term ibrutinib was well tolerated with no new safety signals; rates of grade ≥3 cytopenias decreased with continued therapy.

Referência(s)